alterations,drugs,approvedIndications,level,fdaLevel,levelAssociatedCancerType,levelExcludedCancerTypes,pmids,abstracts,description
['G595R'],"[{'ncitCode': 'C115977', 'drugName': 'Larotrectinib'}]",[],LEVEL_R1,LEVEL_Fda2,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],"['30093503', '31406350', '32133433', '33328556', '26546295', '30624546', '29466156', '28751539', '28578312']","[{'link': 'https://tptherapeutics.com/wp-content/uploads/AACR_2019_TRK_Final_S.pdf', 'abstract': 'Drilon et al. Abstract# 4000, AACR 2019.'}]","Larotrectinib is a small-molecule inhibitor of NTRK1/2/3 that is FDA-approved for the treatment of adult and pediatric patients with solid tumors that have an NTRK gene fusion without a known acquired resistance mutation. NTRK1 G595R is listed in the FDA label for larotrectinib as a clinically supported resistance mutation. At least nine patients representing multiple solid cancer types across multiple studies have demonstrated resistance to larotrectinib after acquiring an NTRK1 G595R mutation in the context of an otherwise NTRK1-fusion-positive, larotrectinib-sensitive tumor (PMID: 30624546, 31406350, 29466156, 33328556, 28578312, 30093503, 32133433, 26546295, 28751539)(Abstract: Drilon et al. Abstract# 4000, AACR 2019. https://tptherapeutics.com/wp-content/uploads/AACR_2019_TRK_Final_S.pdf)."
['G595R'],"[{'ncitCode': 'C138160', 'drugName': 'Selitrectinib'}]",[],LEVEL_3A,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],"['28578312', '32133433', '33004339']",[],"Selitrectinib is an orally available, small-molecule NTRK tyrosine kinase inhibitor. There are promising clinical data in patients with NTRK1 G595R-mutant solid tumors treated with selitrectinib. Case studies of patients with NTRK1-rearranged solid tumors (n=2, TPM3-NTRK1-rearranged sarcoma; n=1, LMNA-NTRK1-rearranged colorectal cancer; n=1, LMNA-NTRK1-rearranged breast cancer) expressing acquired NTRK1 G595R treated with selitrectinib demonstrated three partial responses (n=2, sarcoma; n=1, colorectal cancer) and one mixed response (n=1, breast cancer) (PMID: 32133433, 33004339). Preclinical studies of xenograft mouse models and cell lines expressing NTRK1 G595R demonstrate sensitivity to selitrectinib as measured by tumor growth inhibition upon drug treatment (PMID: 28578312)."
['G595R'],"[{'ncitCode': 'C179627', 'drugName': 'Zurletrectinib'}]",[],LEVEL_4,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],['38902532'],[],"Zurletrectinib is an orally available, small-molecule pan-NTRK tyrosine kinase inhibitor. There are promising laboratory data that suggest that NTRK1 G595R may be sensitive to zurletrectinib. Preclinical studies with NTRK-rearranged cell lines and xenograft models expressing NTRK1 G595R demonstrate sensitivity to zurletrectinib as measured by reduced cellular viability and downstream signaling and tumor growth inhibition upon drug treatment (PMID: 38902532)."
['G595R'],"[{'ncitCode': 'C114984', 'drugName': 'Entrectinib'}]",[],LEVEL_R2,LEVEL_Fda3,"{'id': 984, 'code': '', 'color': '', 'name': '', 'mainType': {'id': None, 'name': 'All Solid Tumors', 'tumorForm': 'SOLID'}, 'tissue': '', 'children': {}, 'parent': None, 'level': -1, 'tumorForm': 'SOLID'}",[],"['26546295', '28751539']","[{'link': 'https://tptherapeutics.com/wp-content/uploads/AACR_2019_TRK_Final_S.pdf', 'abstract': 'Drilon et al. Abstract# 4000, AACR 2019.'}]","Entrectinib is an ATP-competitive tyrosine kinase inhibitor that is highly effective against NTRK1/2/3, ROS1 and ALK and is FDA-approved for patients with NTRK-fusion-positive solid tumors. The NTRK1 G595R mutation has been found in patients whose tumors have progressed on first-generation NTRK inhibitors such as larotrectinib and entrectinib. A patient with LMNAâ€“NTRK1 fusion-positive colorectal cancer had a partial response for four months with entrectinib before the progression and acquisition of G595R and G667C mutations in separate clones (PMID: 26546295). Preclinical studies have demonstrated the resistance of NTRK1 G595R to entrectinib (PMID: 28751539, 28751539, 26546295)(Abstract: Drilon et al. Abstract# 4000, AACR 2019. https://tptherapeutics.com/wp-content/uploads/AACR_2019_TRK_Final_S.pdf)."
